awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q53828883-0690EE77-09BB-4677-BD62-30363A767A8F
Q53828883-0690EE77-09BB-4677-BD62-30363A767A8F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53828883-0690EE77-09BB-4677-BD62-30363A767A8F
Management of Moderate to Severe Plaque Psoriasis: The Emerging Role of IL-17 Inhibition.
P2860
Q53828883-0690EE77-09BB-4677-BD62-30363A767A8F
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53828883-0690EE77-09BB-4677-BD62-30363A767A8F
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
eaf9323e5821815ee9043745a4d488cddc9b111c
P2860
Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A)